المؤلفون: Zhou, Chenfei¹ (AUTHOR), Wang, Bin² (AUTHOR), Teng, Christina³ (AUTHOR), Yang, Hui¹ (AUTHOR), Piha-Paul, Sarina A.⁴ (AUTHOR), Richardson, Gary⁵ (AUTHOR), Malalasekera, Ashanya⁶ (AUTHOR), Sun, Yajun⁷ (AUTHOR), Wang, Wei² (AUTHOR), Liu, Jieqiong⁸ (AUTHOR) liujieqiong01@163.com, Shi, Yan¹ (AUTHOR) shibaiwan12@vip.sina.com, Zhan, Xianbao² (AUTHOR) zhanxianbao@csco.org.cn, Lemech, Charlotte³ (AUTHOR) charlotte.lemech@scientiaclinicalresearch.com.au

المصدر: Journal of Translational Medicine. 1/9/2025, Vol. 23 Issue 1, p1-11. 11p.

مصطلحات موضوعية: *EPIDERMAL growth factor receptors, *SALIVARY gland cancer, *ADVERSE health care events, *PLATELET count, *PREVENTIVE medicine

المؤلفون: Pikul, Julia¹ (AUTHOR), Machnicki, Marcin M.² (AUTHOR), Rzepakowska, Anna¹ (AUTHOR) arzepakowska@wum.edu.pl, Winiarska, Natalia³ (AUTHOR), Chudy, Agnieszka⁴ (AUTHOR), Moskowicz, Albert⁴ (AUTHOR), Król, Kacper³ (AUTHOR), Fus, Łukasz⁵ (AUTHOR), Kostrzewa, Grażyna⁶ (AUTHOR), Stokłosa, Tomasz² (AUTHOR)

المصدر: BMC Cancer. 1/8/2025, Vol. 25 Issue 1, p1-15. 15p.

مصطلحات موضوعية: *SALIVARY gland cancer, *MEDICAL sciences, *ADENOID cystic carcinoma, *CANCER relapse, *OVERALL survival

المؤلفون: Linxweiler, Maximilian¹ (AUTHOR) maximilian.linxweiler@uks.eu, Wemmert, Silke¹ (AUTHOR), Braun, Felix Leon¹ (AUTHOR), Körner, Sandrina¹ (AUTHOR), Brust, Lukas Alexander¹ (AUTHOR), Knebel, Moritz¹ (AUTHOR), Klamminger, Gilbert Georg² (AUTHOR), Wagner, Mathias² (AUTHOR), Morris, Luc G. T.^3,4 (AUTHOR), Kühn, Jan Philipp¹ (AUTHOR)

المصدر: Molecular Diagnosis & Therapy. Jan2025, Vol. 29 Issue 1, p103-115. 13p.

مصطلحات موضوعية: *SALIVARY gland cancer, *ANDROGEN receptors, *MEDICAL sciences, *FLUORESCENCE in situ hybridization, *PROTEIN expression

المؤلفون: Hung, Shih-Han^1,2,3 (AUTHOR), Yang, Tzong-Hann^4,5,6,7,8 (AUTHOR), Lee, Hsin-Chien^9,10 (AUTHOR), Lin, Herng-Ching^11,12 (AUTHOR), Chen, Chin-Shyan^8,13 (AUTHOR) stan@mail.ntpu.edu.tw

المصدر: European Archives of Oto-Rhino-Laryngology. Jan2025, Vol. 282 Issue 1, p403-408. 6p.

مصطلحات موضوعية: *SALIVARY gland cancer, *HUMAN papillomavirus, *PAPILLOMAVIRUS diseases, *MEDICAL sciences, *ALCOHOLISM

المؤلفون: Nagatani, Yoshiaki¹ (AUTHOR), Kiyota, Naomi^1,2 (AUTHOR) nkiyota@med.kobe-u.ac.jp, Imamura, Yoshinori¹ (AUTHOR), Koyama, Taiji¹ (AUTHOR), Funakoshi, Yohei¹ (AUTHOR), Komatsu, Masato³ (AUTHOR), Itoh, Tomoo³ (AUTHOR), Teshima, Masanori⁴ (AUTHOR), Nibu, Ken‐Ichi⁴ (AUTHOR), Sakai, Kazuko⁵ (AUTHOR), Nishio, Kazuto⁵ (AUTHOR), Shimomura, Manami⁶ (AUTHOR), Nakatsura, Tetsuya⁶ (AUTHOR), Ikarashi, Daiki⁶ (AUTHOR), Nakayama, Takayuki⁶ (AUTHOR), Kitano, Shigehisa⁷ (AUTHOR), Minami, Hironobu^1,2 (AUTHOR)

المصدر: Asia Pacific Journal of Clinical Oncology. Dec2024, Vol. 20 Issue 6, p779-788. 10p.

مصطلحات موضوعية: *SUPPRESSOR cells, *SALIVARY gland cancer, *ADENOID cystic carcinoma, *MUCOEPIDERMOID carcinoma, *IMMUNE checkpoint inhibitors

المؤلفون: Pusztaszeri, Marc¹ marc.pusztaszeri@mcgill.ca, Rossi, Esther Diana², Faquin, William C.³

المصدر: Archives of Pathology & Laboratory Medicine. Oct2024, Vol. 148 Issue 10, p1092-1104. 13p.

مصطلحات موضوعية: *SALIVARY gland tumors, *NEEDLE biopsy, *COMMUNICATION, *SALIVARY gland diseases, *EVIDENCE-based medicine, *PHYSICIANS, *QUALITY assurance

المؤلفون: Mujtaba, Hasan¹ (AUTHOR), Ahmad, Shahzad² (AUTHOR) shahzaddentist@yahoo.com, Khan, Zafar Ali³ (AUTHOR), Issrani, Rakhi^4,5 (AUTHOR), Munisekhar, Manay Srinivas⁶ (AUTHOR), Iqbal, Shazia² (AUTHOR), Javed, Danish⁷ (AUTHOR), Alqarni, Mohammed Saad⁸ (AUTHOR), Batool, Iffat⁹ (AUTHOR), Alotha, Salah Nazal¹⁰ (AUTHOR), Alsiyat, Basant Mousa¹⁰ (AUTHOR), Khan, Tahir Ullah¹¹ (AUTHOR)

المصدر: Journal of Cancer Research & Therapeutics. Oct-Dec2024, Vol. 20 Issue 6, p1872-1877. 6p.

مصطلحات موضوعية: *ADENOID cystic carcinoma, *SALIVARY gland cancer, *IMMUNOSTAINING, *SALIVARY glands, *HEMATOXYLIN & eosin staining

المؤلفون: Itoyama, Mai¹ (AUTHOR), Ohara, Akihiro¹ (AUTHOR), Yokoyama, Kazuki¹ (AUTHOR), Yamamoto, Shun¹ (AUTHOR), Kato, Ken¹ (AUTHOR), Tada, Yuichiro² (AUTHOR), Sugitani, Ayumi³ (AUTHOR), Sugino, Hirokazu³ (AUTHOR), Yatabe, Yasushi³ (AUTHOR), Kusumoto, Masahiko⁴ (AUTHOR), Nakamura, Kenichi⁵ (AUTHOR), Honma, Yoshitaka¹ (AUTHOR) yohonma@ncc.go.jp

المصدر: Auris Nasus Larynx. Oct2024, Vol. 51 Issue 5, p829-833. 5p.

مصطلحات موضوعية: *SALIVARY gland cancer, *PAROTID glands, *COMPUTED tomography, *DISEASE progression

المؤلفون: Winkelmann, Ria¹ (AUTHOR) maja.white@web.de, Weißgerber, Maja¹ (AUTHOR) peter.wild@ukffm.de, Wild, Peter J.^1,2 (AUTHOR) julia.bein@ukffm.de, Bein, Julia¹ (AUTHOR) melanie.demes@unimedizin-ffm.de, Fleischmann, Maximilian³ (AUTHOR) fleischmann@med.uni-frankfurt.de, Demes, Melanie¹ (AUTHOR) katrin.bankov@charite.de, Balermpas, Panagiotis^3,4 (AUTHOR) panagiotis.balermpas@usz.ch, Loth, Andreas⁵ (AUTHOR) andreas.loth@unimedizin-ffm.de, Bankov, Katrin^1,6 (AUTHOR), von der Grün, Jens^3,4 (AUTHOR) jens.vondergruen@usz.ch

المصدر: Life (2075-1729). Sep2024, Vol. 14 Issue 9, p1089. 12p.

مصطلحات موضوعية: *SALIVARY gland cancer, *P53 protein, *SALIVARY glands, *IMMUNOHISTOCHEMISTRY, *UNIVARIATE analysis

مصطلحات جغرافية: BETHESDA (Md.)

المؤلفون: Brajkovic, Denis^1,2 (AUTHOR) denis.brajkovic@mf.uns.ac.rs, Kiralj, Aleksandar^1,2 (AUTHOR), Ilic, Miroslav^1,2 (AUTHOR), Mijatov, Ivana^1,2 (AUTHOR)

المصدر: European Archives of Oto-Rhino-Laryngology. Sep2024, Vol. 281 Issue 9, p4947-4962. 16p.

مصطلحات موضوعية: *SALIVARY gland cancer, *SALIVARY glands, *PROGNOSIS, *OVERALL survival, *PAROTID glands, *ADENOID cystic carcinoma

المؤلفون: Haigh, Joseph Edward¹ (AUTHOR) joseph.haigh3@nhs.net, Patel, Karan¹ (AUTHOR), Rack, Sam¹ (AUTHOR), Jiménez-Labaig, Pablo^2,3,4 (AUTHOR), Betts, Guy⁵ (AUTHOR), Harrington, Kevin Joseph^2,4 (AUTHOR), Metcalf, Robert¹ (AUTHOR) robert.metcalf1@nhs.net

المصدر: Current Oncology. Sep2024, Vol. 31 Issue 9, p5652-5661. 10p.

مصطلحات موضوعية: *SALIVARY gland cancer, *TERMINATION of treatment, *PLEOMORPHIC adenoma, *TREATMENT duration, *GROUP psychotherapy

المؤلفون: Jazz Pharmaceuticals Ireland Limited

المصدر: A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Other URLs: https://www.jazzpharma.com/science/clinical-trial-data-sharing

المصدر: A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Characterization of Diseases With Salivary Gland Involvement
Yin H, Pranzatelli TJF, French BN, Zhang N, Warner BM, Chiorini JA; NIDCD/NIDCR Genomics and Computational Biology Core. Sclerosing Sialadenitis Is Associated With Salivary Gland Hypofunction and a Unique Gene Expression Profile in Sjogren's Syndrome. Front Immunol. 2021 Jul 30;12:699722. doi: 10.3389/fimmu.2021.699722. eCollection 2021.
Tanaka T, Warner BM, Odani T, Ji Y, Mo YQ, Nakamura H, Jang SI, Yin H, Michael DG, Hirata N, Suizu F, Ishigaki S, Oliveira FR, Motta ACF, Ribeiro-Silva A, Rocha EM, Atsumi T, Noguchi M, Chiorini JA. LAMP3 induces apoptosis and autoantigen release in Sjogren's syndrome patients. Sci Rep. 2020 Sep 16;10(1):15169. doi: 10.1038/s41598-020-71669-5.

المؤلفون: National Cancer Institute (NCI)

المصدر: "CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial"

المؤلفون: National Cancer Institute (NCI)

المصدر: A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer

المصدر: Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Other URLs: https://grants.nih.gov/policy/sharing.htm

المؤلفون: Ascentage Pharma Group Inc.

المصدر: A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma

المصدر: An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma

Other URLs: https://www.janssen.com/clinical-trials/transparency

المصدر: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Sullivan WG, Hatswell AJ. Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'. ESMO Open. 2021 Dec;6(6):100282. doi: 10.1016/j.esmoop.2021.100282. Epub 2021 Oct 28. No abstract available.
Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs MG, Meropol NJ, Wong WB, Crane G. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24. Erratum In: J Comp Eff Res. 2022 May;11(7):545-548. doi: 10.2217/cer-2021-0131c1.
Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Erratum In: Lancet Oncol. 2020 Feb;21(2):e70. doi: 10.1016/S1470-2045(20)30007-3. Lancet Oncol. 2020 Jul;21(7):e341. doi: 10.1016/S1470-2045(20)30346-6.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum In: Lancet Oncol. 2020 Feb;21(2):e70. doi: 10.1016/S1470-2045(20)30029-2. Lancet Oncol. 2020 Jul;21(7):e341. doi: 10.1016/S1470-2045(20)30345-4. Lancet Oncol. 2020 Aug;21(8):e372. doi: 10.1016/S1470-2045(20)30382-X. Lancet Oncol. 2021 Oct;22(10):e428. doi: 10.1016/S1470-2045(21)00538-6.
Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322. doi: 10.6004/jnccn.2017.7029.